中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
16期
109-110,111
,共3页
茵栀黄口服液%新生儿%胆道闭锁%临床疗效%细胞因子
茵梔黃口服液%新生兒%膽道閉鎖%臨床療效%細胞因子
인치황구복액%신생인%담도폐쇄%림상료효%세포인자
Yinzhihuang Oral Liquid%newborn%biliary atresia%clinical efficacy%cytokine
目的：探讨茵栀黄口服液治疗胆道闭锁的临床疗效及安全性。方法将42例胆道闭锁患儿随机分为对照组和治疗组，各21例。对照组采用肝门空肠吻合术（Kasai 手术）及药物常规治疗，治疗组在此基础上于手术前后口服茵栀黄口服液。观察两组患儿的临床疗效，于治疗前后检测血生化指标和细胞因子水平，并记录药品不良反应；随访半年，观察胆管炎的发作情况及肝纤维化程度。结果治疗后，治疗组总有效率为90.48%，明显高于对照组的71.43%（ P <0.05）；两组患儿治疗后血生化指标和细胞因子水平均较治疗前明显降低，且治疗组比对照组下降更显著（ P <0.05）；治疗组出现药品不良反应3例，症状均较轻微；随访半年，治疗组和对照组胆管炎发生率分别为9.52%和23.81%，肝纤维化异常率分别为9.52%和28.57%，但差异无统计学意义（ P >0.05）。结论胆道闭锁新生儿在行Kasai 手术及常规药物治疗的基础上，加用口服茵栀黄口服液，可显著提高临床疗效，调节患儿免疫功能，且不良反应较少，值得推广。
目的：探討茵梔黃口服液治療膽道閉鎖的臨床療效及安全性。方法將42例膽道閉鎖患兒隨機分為對照組和治療組，各21例。對照組採用肝門空腸吻閤術（Kasai 手術）及藥物常規治療，治療組在此基礎上于手術前後口服茵梔黃口服液。觀察兩組患兒的臨床療效，于治療前後檢測血生化指標和細胞因子水平，併記錄藥品不良反應；隨訪半年，觀察膽管炎的髮作情況及肝纖維化程度。結果治療後，治療組總有效率為90.48%，明顯高于對照組的71.43%（ P <0.05）；兩組患兒治療後血生化指標和細胞因子水平均較治療前明顯降低，且治療組比對照組下降更顯著（ P <0.05）；治療組齣現藥品不良反應3例，癥狀均較輕微；隨訪半年，治療組和對照組膽管炎髮生率分彆為9.52%和23.81%，肝纖維化異常率分彆為9.52%和28.57%，但差異無統計學意義（ P >0.05）。結論膽道閉鎖新生兒在行Kasai 手術及常規藥物治療的基礎上，加用口服茵梔黃口服液，可顯著提高臨床療效，調節患兒免疫功能，且不良反應較少，值得推廣。
목적：탐토인치황구복액치료담도폐쇄적림상료효급안전성。방법장42례담도폐쇄환인수궤분위대조조화치료조，각21례。대조조채용간문공장문합술（Kasai 수술）급약물상규치료，치료조재차기출상우수술전후구복인치황구복액。관찰량조환인적림상료효，우치료전후검측혈생화지표화세포인자수평，병기록약품불량반응；수방반년，관찰담관염적발작정황급간섬유화정도。결과치료후，치료조총유효솔위90.48%，명현고우대조조적71.43%（ P <0.05）；량조환인치료후혈생화지표화세포인자수평균교치료전명현강저，차치료조비대조조하강경현저（ P <0.05）；치료조출현약품불량반응3례，증상균교경미；수방반년，치료조화대조조담관염발생솔분별위9.52%화23.81%，간섬유화이상솔분별위9.52%화28.57%，단차이무통계학의의（ P >0.05）。결론담도폐쇄신생인재행Kasai 수술급상규약물치료적기출상，가용구복인치황구복액，가현저제고림상료효，조절환인면역공능，차불량반응교소，치득추엄。
Objective To investigate the clinical efficacy and security of Yinzhihuang Oral Liquid in treating neonatal biliary atresi-a. Methods 42 cases of neonatal biliary atresia were randomly divided into the treatment group and the control group,21 cases in each group. The control group was treated with hepatic portal jejunal anastomosis(Kasai surgery)and routine medication therapy and on this basis the treatment group orally took Yinzhihuang Oral Liquid before operation. The clinical efficacy was observed in the two groups. Serum biochemical indexes and cytokine levels were examined before and after treatment. The drug adverse reactions were recorded. Follow - up lasted for half a year. The onset of cholangitis and liver fibrosis degree were observed. Results The total effec-tive rate after treatment in the treatment group was 90. 48% ,which was significantly higher than 71. 43% in the control group( P <0. 05);the levels of serum biochemical indexes and cytokines after treatment in the two groups were decreased compared with before treatment,but the decrease in the treatment group was more significant compared with the control group( P < 0. 05);the treatment group had 3 cases of adverse reactions,the clinical symptoms were mild;in follow - up for half a year,the incidence rate of cholangitis in the treatment group and the control group were 9. 52% and 23. 81% respectively,the abnormal rate of hepatic fibrosis were 9. 52% and 28. 57% respectively,but the differences were not statistically significant( P > 0. 05). Conclusion On the basis of performing Kasai surgery and the routine medication for treating neonatal biliary atresia,adding Yinzhihuang Oral Liquid can significantly increase the clinical efficacy and adjust the immune function with less adverse reactions,which is worth clinical promotion.
